Physician profile
Franklin Lowe
NPI 1629097613
$15,443.20
in general payments reported to CMS, 2019-2025
72 companies · $2,445 in 2025
The $2,445 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,838 · 2020: $2,117 · 2021: $2,271 · 2022: $2,133 · 2023: $2,220 · 2024: $2,420 · 2025: $2,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,046 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37.10 · Education: $1.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,046.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37.10 |
| Education | $1.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,723.04 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $1,186.88 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $887.59 | 2019-2025 | |
| Glaxosmithkline, LLC. | $818.17 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $754.72 | 2019-2025 | Cuvitru, Hyqvia, Trintellix |
| Lilly USA, LLC | $668.97 | 2019-2025 | Mounjaro, Kisunla, Jardiance |
| Amarin Pharma, INC. | $640.45 | 2019-2022 | |
| Bausch Health US, LLC | $605.68 | 2022-2025 | Aplenzin, Wellbutrin |
| Astrazeneca Pharmaceuticals LP | $578.41 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Radius Health, INC. | $552.03 | 2020-2025 | Tymlos |
| Grifols USA, LLC | $407.29 | 2021-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Regeneron Healthcare Solutions, INC. | $405.59 | 2019-2021 | |
| Horizon Therapeutics Plc | $365.17 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $330.18 | 2019-2022 | |
| Cleerly, INC. | $321.85 | 2024-2025 | Cleerly Labs, Cleerly Ischemia |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franklin Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.